ICCC - IMMUCELL CORP /DE/
6.52
-0.010 -0.153%
Share volume: 9,481
Last Updated: 03-27-2026
Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances:
-0.08%
PREVIOUS CLOSE
CHG
CHG%
$6.53
-0.01
0.00%
Fundamental analysis
40%
Profitability
28%
Dept financing
29%
Liquidity
41%
Performance
55%
Performance
5 Days
1.72%
1 Month
-0.31%
3 Months
6.02%
6 Months
5.50%
1 Year
30.14%
2 Year
23.02%
Key data
Stock price
$6.52
DAY RANGE
$6.35 - $6.52
52 WEEK RANGE
$4.52 - $7.60
52 WEEK CHANGE
$36.12
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-14-2025
Company detail
CEO: Michael F. Brigham
Region: US
Website: immucell.com
Employees: 70
IPO year: 1995
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances
Sector: Manufacturing
Region: US
Website: immucell.com
Employees: 70
IPO year: 1995
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances
Sector: Manufacturing
ImmuCell Corporation develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine which quarter of the udder is mastitic.
Recent news